



# BÜHLMANN Quantum Blue® Therapeutic Drug Monitoring References

- Schuster. T *et al.* *ECCO 2016*. Performance of the BÜHLMANN Quantum Blue® Infiximab point-of-care assay dedicated for therapeutic drug monitoring of serum infiximab trough levels.  
“Quantum Blue Infiximab assay enables the quantitative determination of the infiximab trough level in serum with a time to result of only 15 minutes and exhibits an excellent correlation with existing ELISAs”
- Afonso. J *et al.* *Alimentary Pharmacology and Therapeutics 2016*. Proactive therapeutic drug monitoring of infiximab: A comparative study with a new point of care quantitative test with two established ELISA assays.  
“The Quantum Blue IFX assay can successfully replace the commonly used ELISA-based IFX quantification kits. This point-of-care IFX assay is able to deliver the results within 15 minutes makes it ideal for an immediate target concentration adjusted dosing. Moreover, it is a user-friendly desktop device that does not require specific laboratory facilities or highly specialised personnel”
- Margo. F *et al.* *Therapeutic Advances in Gastroenterology 2017*. Clinical performance of an infiximab rapid quantification assay.  
“using the rapid IFX assessment system with a 3µg/ml threshold is a reliable alternative to the time consuming ELISA assays in patients on the maintenance phase of IFX”
- Wieser. M *et al.* *UEGW 2017*. Performance of the BÜHLMANN Quantum Blue Adalimumab rapid test dedicated for therapeutic drug monitoring of serum adalimumab trough levels.  
“The Quantum Blue adalimumab test enables the quantitative determination of adalimumab levels from 1 to 35µg/ml in serum with a time to result of only 15 minutes”
- Afonso. J *et al.* *Therapeutic Advances in Gastroenterology 2017*. Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays.  
“The QB kit has the added advantage of being a bedside point-of-care solution, releasing results within 15 min of sampling, and therefore allowing an immediate adjustment of CT-P13 dosing”
- Bantleon. F *et al.* *ECCO 2017*. Quantum Blue Adalimumab: Development of the first point of care rapid test for therapeutic drug monitoring of serum adalimumab levels.  
“The developed assay allows to measure adalimumab over a wide range. Hence it represents a valuable tool for the clinicians to assess the adalimumab trough level”
- Fellay B *et al.* *ECCO 2018*. Quantum Blue Infiximab POC user performance evaluation. Quantum Blue infiximab POC system which determines infiximab levels in serum specimens, is easy-to-use, the given instructions are comprehensive, and the results are comparable between different POC sites as well as between POC sites and laboratories”
- Restellini. S *et al.* *ECCO 2018*. A pilot study using point of care testing for infiximab and fecal calprotectin in inflammatory bowel disease patients with a secondary loss of response.  
“Using POC testing for IFX patients with a secondary LOR is clinically useful, correlates well with standardized testing, allows for immediate appropriate management of patients and results in a rapid clinical remission as early as 4 weeks”

- Rentsch. C et al. ECCO 2018. Pharmacist-led proactive therapeutic drug monitoring with infliximab (PROXIMO): utility of and cost saving with the use of a rapid assay for assessing drug level.  
“This rapid test strategy has the potential to reduce patient risks and improve patient outcomes without negative cost implications”
- Strik. A et al. ECCO 2018. Validation of the Quantum Blue Infliximab level rapid test in clinical practice of patients with inflammatory bowel disease.  
“ It is a good alternative for the conventional ELISA method for the measurement of IFX serum concentrations at trough in IBD patients receiving IFX maintenance treatment”

### **Use in clinic:**

- Lindsjo. I et al. UEGW 2016. Patient-near infliximab trough-level testing by a novel quantitative rapid test: The Quantum Blue Infliximab test.  
“the test can accurately be performed by a nurse which means that |TDM now can be moved from a distant laboratory to the near patient facility like the infusion centre and ensure correct dosing in IBD and other patients on IFX treatment”
- Costa Santos. M et al. ECCO 2018. Point-of-care infliximab quantification in inflammatory bowel disease in daily practice.  
“POC IFX-TL measurement was easy to implement on a daily clinical practice setting. IFX-TL considered to be within the therapeutic range were found in one-third of patients. In the remaining patients an immediate treatment adjustment could have been made allowing for resource saving”

### **Use with Biosimilars:**

- Afonso. J et al. ECCO 2017. The new infliximab point-of-care quantitative test can equally be used for therapeutic drug monitoring of biosimilars of infliximab.  
“POC IFX assay revealed an excellent average spiking recovery percentage 102%”
- Magro. F et al. ECCO 2018. The new biosimilar of infliximab SB2 can be quantified by IFX-optimised therapeutic drug monitoring assays.  
“The tested assays can be safely used to monitor drug levels in patients medicated with IFX biosimilar SB2”